CA3161509A1 - Preparation of trifarotene and intermediates and polymorphs thereof - Google Patents
Preparation of trifarotene and intermediates and polymorphs thereof Download PDFInfo
- Publication number
- CA3161509A1 CA3161509A1 CA3161509A CA3161509A CA3161509A1 CA 3161509 A1 CA3161509 A1 CA 3161509A1 CA 3161509 A CA3161509 A CA 3161509A CA 3161509 A CA3161509 A CA 3161509A CA 3161509 A1 CA3161509 A1 CA 3161509A1
- Authority
- CA
- Canada
- Prior art keywords
- trifarotene
- formula
- substituted
- polymorph
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946943P | 2019-12-11 | 2019-12-11 | |
| US62/946,943 | 2019-12-11 | ||
| PCT/US2020/064365 WO2021119351A1 (en) | 2019-12-11 | 2020-12-10 | Preparation of trifarotene and intermediates and polymorphs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3161509A1 true CA3161509A1 (en) | 2021-06-17 |
Family
ID=74141909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3161509A Pending CA3161509A1 (en) | 2019-12-11 | 2020-12-10 | Preparation of trifarotene and intermediates and polymorphs thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11691946B2 (https=) |
| EP (2) | EP4073035B1 (https=) |
| JP (3) | JP7281016B2 (https=) |
| CN (1) | CN114787129B (https=) |
| AU (2) | AU2020402049B2 (https=) |
| CA (1) | CA3161509A1 (https=) |
| ES (1) | ES3037292T3 (https=) |
| IL (2) | IL293800B2 (https=) |
| WO (1) | WO2021119351A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL293800B2 (en) * | 2019-12-11 | 2024-10-01 | Taro Pharma Ind | Preparation of trifarotene and intermediates and polymorphs thereof |
| CN117342993A (zh) * | 2022-07-05 | 2024-01-05 | 石家庄迪斯凯威医药科技有限公司 | 一种曲法罗汀盐及其药物组合物和用途 |
| CN115745913B (zh) * | 2022-09-16 | 2024-05-24 | 南京迈诺威医药科技有限公司 | 曲法罗汀多晶型及其制备方法 |
| JP2026507122A (ja) * | 2023-02-28 | 2026-02-27 | タロー・ファーマシューティカル・インダストリーズ・リミテッド | トリファロテンを調製する方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1248869A2 (en) * | 2000-01-07 | 2002-10-16 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| WO2004083335A2 (en) * | 2003-03-21 | 2004-09-30 | University Of Rochester | Glassy chiral-nematic liquid crystals and optical devices containing same |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| DK1817301T3 (da) * | 2004-11-22 | 2012-02-27 | Lilly Co Eli | Forstærkere af glutamat-receptorer |
| PL1831149T3 (pl) * | 2004-12-23 | 2012-06-29 | Galderma Res & Dev | Nowe ligandy, które modulują receptory RAR, i ich zastosowanie w medycynie i kosmetyce |
| GB2426247A (en) | 2005-05-20 | 2006-11-22 | Arrow Int Ltd | Methods of preparing purine derivatives such as famciclovir |
| EP3475312B1 (en) * | 2016-06-23 | 2020-05-27 | Galderma S.A. | Cyclodextrin-grafted cross-linked hyaluronic acid complexed with active drug substances and uses thereof |
| IL293800B2 (en) * | 2019-12-11 | 2024-10-01 | Taro Pharma Ind | Preparation of trifarotene and intermediates and polymorphs thereof |
-
2020
- 2020-12-10 IL IL293800A patent/IL293800B2/en unknown
- 2020-12-10 JP JP2022534812A patent/JP7281016B2/ja active Active
- 2020-12-10 AU AU2020402049A patent/AU2020402049B2/en active Active
- 2020-12-10 EP EP20838774.6A patent/EP4073035B1/en active Active
- 2020-12-10 EP EP25166751.5A patent/EP4552691A3/en active Pending
- 2020-12-10 ES ES20838774T patent/ES3037292T3/es active Active
- 2020-12-10 IL IL312356A patent/IL312356A/en unknown
- 2020-12-10 CA CA3161509A patent/CA3161509A1/en active Pending
- 2020-12-10 CN CN202080085458.5A patent/CN114787129B/zh active Active
- 2020-12-10 WO PCT/US2020/064365 patent/WO2021119351A1/en not_active Ceased
- 2020-12-10 US US17/756,994 patent/US11691946B2/en active Active
-
2023
- 2023-05-12 JP JP2023079468A patent/JP2023100974A/ja active Pending
- 2023-05-12 US US18/316,742 patent/US20230278956A1/en active Pending
- 2023-09-01 AU AU2023222982A patent/AU2023222982B2/en active Active
-
2025
- 2025-11-07 JP JP2025188194A patent/JP2026016786A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026016786A (ja) | 2026-02-03 |
| IL293800A (en) | 2022-08-01 |
| JP2022550632A (ja) | 2022-12-02 |
| EP4552691A3 (en) | 2025-09-10 |
| IL293800B1 (en) | 2024-06-01 |
| WO2021119351A1 (en) | 2021-06-17 |
| US20230051259A1 (en) | 2023-02-16 |
| CN114787129B (zh) | 2025-07-04 |
| AU2023222982B2 (en) | 2025-01-02 |
| EP4073035B1 (en) | 2025-05-07 |
| NZ788464A (en) | 2024-07-05 |
| IL293800B2 (en) | 2024-10-01 |
| EP4073035A1 (en) | 2022-10-19 |
| US11691946B2 (en) | 2023-07-04 |
| IL312356A (en) | 2024-06-01 |
| JP7281016B2 (ja) | 2023-05-24 |
| JP2023100974A (ja) | 2023-07-19 |
| EP4552691A2 (en) | 2025-05-14 |
| AU2020402049B2 (en) | 2023-06-01 |
| CN114787129A (zh) | 2022-07-22 |
| AU2023222982A1 (en) | 2023-09-21 |
| US20230278956A1 (en) | 2023-09-07 |
| AU2020402049A1 (en) | 2022-06-09 |
| ES3037292T3 (en) | 2025-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3161509A1 (en) | Preparation of trifarotene and intermediates and polymorphs thereof | |
| JP6851454B2 (ja) | キラルジペプチジルペプチダーゼ−ｉｖ阻害剤の製造方法 | |
| CN105859728B (zh) | 一种依鲁替尼的制备方法 | |
| CN105377831B (zh) | 3‑(5‑氨基‑2‑甲基‑4‑氧代喹唑啉‑3(4h)‑基)哌啶‑2，6‑二酮的合成 | |
| AU2015371250B2 (en) | Process of making cenicriviroc and related analogs | |
| CN102627648A (zh) | 一种西他列汀的制备方法 | |
| CN103145632B (zh) | 一种1h-1,2,4-三氮唑-3-甲酸甲酯的制备方法 | |
| WO2023039940A1 (zh) | 一种制备n,n,n-三特戊酰化-1,3,5-三氨基苯的方法 | |
| KR20200061058A (ko) | 비스플루오로술포닐 이미드 알칼리 금속염의 제조방법 및 이에 의해 제조된 비스플루오로술포닐 이미드 알칼리 금속염 | |
| JP4529342B2 (ja) | 環状アミジニウム有機酸塩の製造方法 | |
| WO2024182418A1 (en) | Methods of preparing trifarotene | |
| HK40077817A (zh) | 曲法罗汀及其中间体和多晶型物的制备 | |
| HK40077817B (zh) | 曲法罗汀及其中间体和多晶型物的制备 | |
| CN116621754A (zh) | 吡咯烷酮-3-β’-氨基衍生物的制备方法 | |
| CN114149452B (zh) | 一种l-肌肽锌络合物的制备方法 | |
| CN111718292B (zh) | 一种米力农中间体化合物 | |
| CN121914117A (zh) | 一种制备四氢咪唑并吡嗪衍生物的方法 | |
| KR101669646B1 (ko) | 4-니트로소아닐린의 제조방법 | |
| CN118679154A (zh) | N-(1-甲基环丙基)-2-(3-吡啶基)-2h-吲唑-4-甲酰胺及其中间体的制备 | |
| TW201309633A (zh) | 製備２，２－二氟乙醇的方法 | |
| EA007505B1 (ru) | Способ получения залеплона | |
| KR20120119467A (ko) | 테모카프릴의 제조 중간체로 유용한 아민 화합물의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220929 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240711 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240909 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241002 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250129 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250129 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20250502 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250502 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250507 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251107 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251107 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251107 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251205 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251205 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260106 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260128 |